logo

For the Inventor, By the Inventor

Novate Milanese, Italy

Romeo Ciabatti

This inventor holds 29 USPTO granted patents and 1 published patent application, plus 2 CIPO patents, primarily in Antibiotic Derivatives. Top assignees: Gruppo Lepetit, Biosearch Italia S.p.a., Vicuron Pharmaceuticals Inc.. Active years: 1980-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Romeo Ciabatti. Retrieved from https://idiyas.com/inventor/romeo-ciabatti

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.6

ph-index = 7

Forward Citations = 152(Granted Patents)


Location History:

  • Milan, IT (1980 - 1985)
  • Brodolini, IT (1996)
  • Via Brodolini, IT (1998)
  • Novata Milanese, IT (1999)
  • Novate Milanese, IT (1985 - 2012)

Company Filing History:

goldMedal23 out of 188 
 
Gruppo Lepetit
 patents
silverMedal3 out of 9 
 
Biosearch Italia S.p.a.
 patents
bronzeMedal3 out of 23 
 
Vicuron Pharmaceuticals Inc.
 patents

Years Active: 1980-2012

Loading Chart...
Loading Chart...
Areas of Expertise:
Dalbavancin
Ramoplanin
Antibiotic Derivatives
Prostaglandin Analogues
Rifamycins
Peptide Antibiotics
A 40926
Oxazoline-Amide
Tetrapeptides
Amides
Synthetic Antibiotics
Naphthazarin
29 patents (USPTO):Explore Patents
1. 8143212 - Dalbavancin compositions for treatment of bacterial infections (2012-03-27),
2. 7169890 - Process for the production of ramoplanin-like amide derivatives (2007-01-30),
3. 6720305 - Injectable formulations containing ramoplanin (2004-04-13),
4. 6143739 - Basic proline-amide derivatives of GE 2270 and GE 2270-like antibiotics (2000-11-07),
5. 6008225 - Derivatives of antibiotic GE2270 factors C.sub.2a, D.sub.2 and E (1999-12-28),
6. 5891869 - Basic oxazoline-amide derivatives of GE2270 and GE2270-like antibiotics (1999-04-06),
7. 5869449 - 38-decarboxy-38-hydroxymethyl derivatives of teiocoplanin antibiotics (1999-02-09),
8. 5786350 - 36-derivatives of rifamycins and their use as antimicrobial agents (1998-07-28),
9. 5750509 - Amide derivatives of antibiotic A 40926 (1998-05-12),
10. 5684127 - Tetrapeptides deriving from dalbaheptide antibiotics (1997-11-04),
11. 5674840 - Synthetic aglucodalbaheptide antibiotics (1997-10-07),
12. 5648456 - Pentapeptide antibiotics (1997-07-15),
13. 5644025 - Tetrapeptides deriving from dalbaheptide antibiotics (1997-07-01),
14. 5606036 - Antibiotic A 40926 ester derivatives (1997-02-25),
15. 5602229 - Pentapeptide antibiotics (1997-02-11),

Title: The Innovative Journey of Romeo Ciabatti

Introduction: Romeo Ciabatti, a talented inventor hailing from Novate Milanese, Italy, has made significant contributions to the world of innovations with his creative mind and dedication to progress.

Latest Patents: Romeo Ciabatti's latest patents showcase his commitment to pushing boundaries in various industries, including technology, healthcare, and sustainability. His inventions have been recognized for their ingenuity and practicality.

Career Highlights: Throughout his illustrious career, Romeo Ciabatti has been at the forefront of groundbreaking inventions that have revolutionized the way we live and work. His passion for innovation has led to the development of cutting-edge solutions that address complex challenges.

Collaborations: Romeo Ciabatti has collaborated with leading companies, research institutions, and universities to bring his ideas to life. His ability to work effectively in multidisciplinary teams has resulted in successful partnerships that have propelled his inventions to new heights.

Conclusion: Romeo Ciabatti's innovative spirit and relentless pursuit of excellence continue to inspire the next generation of inventors. His impact on the world of inventions is truly remarkable, and his legacy will endure for years to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…